PolyPeptide Group AG/Fr. PPGN
1D1W1MYTD1Y5YMAX
Capital at risk
About PolyPeptide Group AG
PolyPeptide Group AG operates in the pharmaceutical industry, specializing in the development and manufacture of peptides for various applications. Headquartered in Zug, Switzerland, the company provides essential services and products for the pharmaceutical and biotechnology sectors, including custom peptide synthesis and generic peptide production. With a network of manufacturing facilities across Europe and the United States, PolyPeptide Group AG supports a global clientele. The company's strategic positioning is reinforced by its focus on innovation and quality, ensuring compliance with rigorous industry standards. PolyPeptide's competitive strength lies in its extensive expertise and capabilities in peptide synthesis, serving sectors ranging from therapeutic peptides to cosmetics.
- Ticker
- Fr. PPGN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 1,460
- Headquarters
- Baar, Switzerland
- Website
- www.polypeptide.com
PPGN Metrics
BasicAdvanced
CHF 1.5B
105.18
CHF 0.42
1.00
-
Price and volume
Market cap
CHF 1.5B
Beta
1
52-week high
CHF 50.10
52-week low
CHF 21.80
Average daily volume
130K
Financial strength
Current ratio
1.642
Quick ratio
0.758
Long term debt to equity
0.349
Total debt to equity
0.425
Interest coverage (TTM)
4.16%
Profitability
EBITDA (TTM)
71.425
Gross margin (TTM)
22.86%
Net profit margin (TTM)
3.15%
Operating margin (TTM)
9.63%
Effective tax rate (TTM)
42.56%
Revenue per employee (TTM)
CHF 293,440
Management effectiveness
Return on assets (TTM)
3.38%
Return on equity (TTM)
4.24%
Valuation
Price to earnings (TTM)
105.175
Price to revenue (TTM)
3.312
Price to book
4.15
Price to tangible book (TTM)
4.22
Price to free cash flow (TTM)
-29.794
Free cash flow yield (TTM)
-3.36%
Free cash flow per share (TTM)
-1.48
Growth
Revenue change (TTM)
24.40%
Earnings per share change (TTM)
-142.49%
3-year revenue growth (CAGR)
18.02%
3-year earnings per share growth (CAGR)
-26.51%
Bulls say / Bears say
In H1 2026 PolyPeptide delivered revenue of €236.6 million, up 41.6% year-on-year, while EBITDA more than doubled to €49.1 million and margin expanded to 20.7%, underpinning strong operational leverage. (Reuters)
Full-year 2025 revenues reached €389.3 million, up 15.6% YoY and hitting the midpoint of guidance, with EBITDA margin improving to 12% from 7.5% the prior year, demonstrating effective scale-up of peptide production. (Reuters)
During H1 2026 the company amended its revolving credit facility, increasing bank commitments from €151 million to €200 million and extending the maturity to March 2028, bolstering liquidity for capacity expansion. (PolyPeptide Group AG H1 2026 Half-Year Report)
Polypeptide Group AG announced on April 14, 2026 that it is conducting a review of strategic options, suggesting potential divestiture or restructuring which may reflect concerns over its standalone strategic trajectory. (Reuters)
CFO Marc Augustin is set to resign effective March 31, 2026, introducing finance leadership uncertainty amid execution of ambitious growth and integration plans. (Reuters)
Samsung Biologics’ all-cash takeover bid of CHF 44.31 per share provides only a modest premium over recent trading levels of around CHF 43.95, limiting incremental upside for remaining public shareholders. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Upcoming events
No upcoming events
Funds containing PPGN
AllUSDEURGBP
Fund name | Fund size | Fr. PPGN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.08% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.08% |
iShares Healthcare Innovation£DRDR | £1B | 0.08% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.